Arcutis Biotherapeutics Inc’s recent filing unveils that its Officer Watanabe Todd acquired Company’s shares for reported $0.17 million on Aug 04 ’25. In the deal valued at $14.33 per share,11,547 shares were bought.
Then, Burnett Patrick bought 2,622 shares, generating $37,564 in total proceeds.
Before that, Matsuda Masaru bought 6,330 shares. Arcutis Biotherapeutics Inc shares valued at $90,687 were divested by the Officer at a price of $14.33 per share.
Goldman initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Neutral in a research note published on July 25, 2025; the price target was $18. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late December with a ‘”a Buy”‘ rating. Jefferies began covering ARQT with “Buy” recommendation on August 28, 2024. Mizuho revised its rating on January 03, 2024. It rated ARQT as “a Buy” which previously was an “a Neutral”.
Price Performance Review of ARQT
On Monday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock jump 1.61% to $14.52. Over the last five days, the stock has lost -2.94%. Arcutis Biotherapeutics Inc shares have risen nearly 44.19% since the year began. Nevertheless, the stocks have risen 4.24% over the past one year.
How much short interest is there in Arcutis Biotherapeutics Inc?
A steep rise in short interest was recorded in Arcutis Biotherapeutics Inc stocks on 2025-07-15, dropping by -1.38 million shares to a total of 17.27 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 18.64 million shares. There was a decline of -7.98%, which implies that there is a negative sentiment for the stock.
